Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa

Inclusion Criteria: * DSM-IV criteria for anorexia nervosa, including weight \<85% of ideal body weight (IBW) and amenorrhea for three months; * Age 18-45 years old; * Gastrointestinal tract symptoms; * Non-hormonal method of birth control, which must be used throughout the study. Female patients unable to bear children must have this documented (i.e., tubal ligation, hysterectomy, or post-menopausal, defined as a minimum of one year since the last menstrual period and elevated FSH); * Stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to baseline; * Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures, including daily SC injections and completion of a daily injection log. * Patient has a primary care physician or treatment team managing her care. Exclusion Criteria: * Use of hormone therapy (including but not limited to estrogen, progesterone) or hormonal methods of birth control (i.e., oral, implantable, or injectable) within eight weeks of screening; or Depo-Provera within six months of screening; * Pregnancy, lactation or breastfeeding, or a positive serum or urine pregnancy test, within eight weeks of screening; * History of diabetes mellitus; * History of purging behaviors greater than once monthly within the last three months; * Active substance abuse; * Use of metoclopramide, erythromycin, 5HT3 anti-emetics, or opioid medications within 2 weeks prior to baseline. \[Note: these drugs should also not be used post-baseline\]; * Hematocrit \< 30.0 %, hemoglobin \< 10.0 g/dl, potassium \< 3.0 mmol/L, fasting glucose \> 100 mg/dL, creatinine \> 1.5 mg/dL, AST or ALT \> 1.5 times the upper limit of normal, or abnormal plasma thyroid stimulating hormone (TSH) level; * Currently receiving parenteral feeding or enteral feeding, or presence of a nasogastric or other enteral tube for feeding or decompression; * History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, bariatric procedure, small or large bowel resection; * Clinical suspicion, in the opinion of the investigator, of active or symptomatic peptic ulcer disease, cholelithiasis, colitis, celiac sprue, or inflammatory bowel disease; * Active suicidal ideation; * Beck Depression Inventory-2 score of ≥ 29; * Current inpatient hospitalization; * Allergic or intolerant of egg, milk, wheat or algae, as these are components of the GEBT test meal; * Participation in a clinical study with an investigational medication or device within the 30 days prior to dosing in the present study; * Any other reason, which in the opinion of the Investigator, including severe renal, hepatic or cardiac disease, would confound proper interpretation of the study or expose a patient to unacceptable risk.